The FACILITATE webinar Understanding the secondary use of clinical trial data, which took place on 11 December, is now available online.
We invite you to follow our Stakeholders Virtual Roundtable, which explored the importance of the secondary use of clinical trial data. Alongside patient testimonials, participants gained insights from clinicians, representatives from industry, and regulatory bodies. This inclusive panel ensured a holistic discussion that fostered collaboration between all involved. During the roundtable, our moderator, Nuala Ryan, leaded an engaging discussion centered around these key questions: What does the secondary use of clinical trial data mean to you – as a patient, clinician, pharmaceutical company, or regulatory representative – and why is it important? What are the main challenges or obstacles you have encountered in your experience with the secondary use of this data?
Agenda
Moderator: Nuala Ryan, Takeda, Public Private Partnership Team, Clinical Research Consultant and Patient Advocate
- 2:30-2:35 Opening Session:
- Jean Sposaro: Director, Bristol Myers Squibb Global Industry | Human Advocate for Equity in Access and Informed Decision Making
- 2:35 – 2:45 Progress Overview:
- Johanna Blom: Professor of Psychobiology Pediatric & Behavioral Neuroscience, University of Modena, and IHI FACILITATE Coordinator
- 2:45: 2:50 Q&A
- 2:50 –3:45: Stakeholder Virtual Roundtable:
- Panellists:
- Daniel Theisen, patients’ representative, Director of ALAN – Maladies Rares LuxembourgAna Vieira, patient, Sjögren Europe co-founder & board member, PortugalPaweł Wrona, Neurology Specialist, Investigator, Clinical Research Manager, Jagiellonian University Medical College, PolandManuel Franco-Martin, Director of the Research Group of Institute of Biomedicine of Salamanca (IBSAL), Spain.Rebecca Sudlow, Data Privacy and Sharing Enabling Platform Leader, Roche UKAaron Mann, CEO of the Clinical Research Data Sharing Alliance, USA
- Luca Pani, Luca Pani, MD, Professor of Pharmacology UNIMORE. Former Director General of the Italian Medicines Agency (AIFA) and member of the Committee for Human Medicinal Products (CHMP) of the EMA.
- 3:45-4:00 Q&A
